Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Diamyd Medical AB's enterprise value is $5.76 Mil.
Diamyd Medical AB's EBITDA for the trailing twelve months (TTM) ended in May. 2026 was $-29.55 Mil. Therefore, Diamyd Medical AB's EV-to-EBITDA for today is -0.20.
The historical rank and industry rank for Diamyd Medical AB's EV-to-EBITDA or its related term are showing as below:
DYMDF'
s EV-to-EBITDA Range Over the Past 10 Years
Min: -52.23 Med: -6.53 Max: 462.1
Current: -0.2
During the past 13 years, the highest EV-to-EBITDA of Diamyd Medical AB was 462.10. The lowest was -52.23. And the median was -6.53.
DYMDF's EV-to-EBITDA is ranked worse than 100% of 400
companies
in the Biotechnology industry
Industry Median: 13.065
vs DYMDF: -0.20
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
Diamyd Medical AB (OTCPK:DYMDF) EV-to-EBITDA Explanation
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Diamyd Medical AB's PE Ratio (TTM) for today is calculated as:
Diamyd Medical AB's share price for today is $0.73.
Diamyd Medical AB's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in May. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.192.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
The historical data trend for Diamyd Medical AB's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
DYMDF vs VRTX, REGN, RVMD: EV-to-EBITDA Comparison
For the Biotechnology subindustry, Diamyd Medical AB's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Diamyd Medical AB EV-to-EBITDA vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Diamyd Medical AB's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Diamyd Medical AB's EV-to-EBITDA falls into.
Diamyd Medical AB's current Enterprise Value is $5.76 Mil.
Diamyd Medical AB's EBITDA for the trailing twelve months (TTM) ended in May. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-29.55 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Diamyd Medical AB (DYMDF) has a EV-to-EBITDA of -0.20 as of Aug. 10, 2026. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Diamyd Medical AB. According to the industry distribution chart, Diamyd Medical AB ranks #999999 out of 400 companies in the Biotechnology industry.
Is Diamyd Medical AB's EV-to-EBITDA too high?
Diamyd Medical AB's current EV-to-EBITDA is -0.20. Based on the distribution chart, Diamyd Medical AB ranks #999999 out of 400 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Diamyd Medical AB has a GF Score™ of 41/100, reflecting its overall financial health beyond just this single metric.
How does Diamyd Medical AB's EV-to-EBITDA compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Diamyd Medical AB ranks #999999 out of 400 companies for EV-to-EBITDA. This places Diamyd Medical AB in the lower half of its industry. The industry median EV-to-EBITDA is 13.07. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBITDA for a Biotechnology company?
The median EV-to-EBITDA among Biotechnology companies is 13.07, based on 400 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBITDA mean?
A high EV-to-EBITDA can signal that a stock is expensive relative to its fundamentals. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Diamyd Medical AB. For the Biotechnology industry, the median EV-to-EBITDA is 13.07 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Diamyd Medical AB's current EV-to-EBITDA is -0.20. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Diamyd Medical AB stock overvalued right now?
Diamyd Medical AB (DYMDF) has a current EV-to-EBITDA of -0.20. The stock's GF Value™ is $9.89, compared to a current price of $0.73 — trading 92.6% below its estimated fair value. The current EV-to-EBITDA is -0.20. Diamyd Medical AB's overall GF Score™ is 41/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBITDA calculated?
EV-to-EBITDA is calculated from a company's financial statements. For Diamyd Medical AB (DYMDF), the current EV-to-EBITDA is -0.20 as of Aug. 10, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Diamyd Medical AB (DYMDF) Overvalued in 2026?
Based on GuruFocus' analysis, Diamyd Medical AB stock appears to be undervalued.
The current stock price of $0.73 is trading 92.6% below its estimated GF Value™ of $9.89.
Key valuation signals for DYMDF:
EV-to-EBITDA: -0.20
GF Value™: $9.89 vs. price of $0.73 (92.6% below fair value)
No single metric tells the full story. See the DYMDF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Diamyd Medical AB develops precision medicine therapies for the prevention and treatment of type 1 diabetes using antigen-based immune technology. Its product candidate, Diamyd (rhGAD65/alum), is an antigen-specific immunomodulatory therapy that aims to preserve endogenous insulin production in individuals carrying the HLA DR3-DQ2 genotype and is being evaluated in the registrational Phase 3 DIAGNODE-3 trial in Stage 3 type 1 diabetes, as well as in the DiaPrecise trial in children with Stage 1 and Stage 2 type 1 diabetes. The Company's activities include clinical development, antigen-specific immunotherapy and in-house manufacturing of recombinant GAD65.
41GF Score
Get the complete analysis for DYMDF
EV-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
DYMDF has been successfully added to your 
